Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate.

ABSTRACT:

Background

Vitamin K antagonists (VKA) are used for the treatment of thromboembolism. Patients with severe VKA-associated bleeding require immediate restoration of haemostasis. Clinical studies on the effect of prothrombin complex concentrate (PCC) are heterogeneous with respect to outcome of bleeding.

Objective

To evaluate the clinical outcome of patients treated with PCC for VKA-associated bleeding.

Methods

We performed a cohort study of consecutive patients who received PCC for VKA-related bleeding in five Dutch hospitals. Data were collected by chart review on the bleeding event, international normalized ratio (INR), haemostatic efficacy, thromboembolic (TE) complications, and mortality. The primary outcome was effective haemostasis, assessed by an adaptation of t

SUBMITTER: Brekelmans MPA 

PROVIDER: S-EPMC6055482 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature